SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jay Lowe who wrote (206)5/18/1998 7:03:00 PM
From: muddphudd  Read Replies (1) of 586
 
Hi Jay,

I got a call from Debby Jo Blank (President and COO). She was at the airport returning calls while waiting for a flight.

She caught me off guard but I managed to ask her some of the questions that have come up.

Regarding any potential future applications of the Prosorba column, she said that since they are a small operation they are focused entirely on the RA PMA right now. They will assess the possibilities at a later time.

They plan on assembling and launching a typical product-launch campaign for the RA application. This will included detailing rheumatologists at their offices about the column.

They are currently evaluating the price they will charge for the Prosorba column treatments. It is their hope to provide the technology at a cheaper price than it is now (for ITP).

As for reimbursements/insurance etc. the Prosorba column is fully reimbursed for treatment of ITP. They are preparing documents, through a company that specializes in medical reimbursement, to present to Health Care Finance Administration (HCFA) and HMOs for new reimbursement for RA.

Where will patients receive this treatment? She detailed 3 options they are considering at this time:
(A) University Medical Center (usual route for plasmapheresis).
(B) National Dialysis Centers with a big presence in the market.
(C) Mobile apharesis units at Rheumatologists offices (under consideration now).

Again, the Prosorba column will be reserved for patients refractory to other less-invasive therapies.

That is it for now.

She was very pleasant.

Go CYPB!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News